You are a research planner for a forecasting question. Your task is to design a search strategy that gives forecasters the best possible evidence base.

QUESTION:
Will PFE's market close price on 2026-03-13 be higher than its market close price on 2026-03-02?

Type: binary

Background:
Pfizer Inc. is a company that is listed on the S&P 500 index. It's ticker is PFE. It's last close price as of the creation of this question (2026-03-01 16:40:53) is 27.65. You can find more information about Pfizer Inc. at https://finance.yahoo.com/quote/PFE

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

`{"format":"close_price_rises","info":{"ticker":"PFE"}}`

Resolution criteria:
This question will resolve based on the latest market close price of PFE. If it is higher than the close price on 2026-03-02, the question will resolve to 'Yes'. The close price will be pulled from the Yahoo Finance API.

Fine print:
Stock splits and reverse splits will be accounted for in resolving this question. Forecasts on questions about companies that have been delisted (through mergers or bankruptcy) will resolve to their final close price.



Question metadata:
- Opened: 2026-03-02T08:24:21Z
- Resolves: 2026-03-13T01:26:47Z
- Today: 2026-03-02 (11 days until resolution)

PRE-RESEARCH CONTEXT:
The following information has already been gathered from sources referenced in the question. Use this to avoid redundant queries and to identify what additional research is needed.


<QuestionSource url="https://finance.yahoo.com/quote/PFE">
## Summary of Yahoo Finance Article on PFE (Pfizer Inc.)

**Disclaimer:** The article content appears to be a partially extracted Yahoo Finance stock page, with some formatting artifacts and incomplete sections. Some data points may reflect a snapshot from around late February/early March 2026.

---

### Key Price & Trading Data
- **Previous Close:** $27.10
- **Open:** $27.16
- **Day's Range:** $27.09 – $27.67
- **52-Week Range:** $20.92 – $27.94
- **Volume:** 29,724,256 (vs. Avg. Volume of 47,872,928)
- **1-Year Price Target (Analyst Consensus):** $28.43

### Valuation & Financials
- **Market Cap:** $157.21B
- **Forward P/E:** 9.33 (vs. Trailing P/E of 20.33)
- **Revenue (TTM):** $62.58B
- **Net Income (TTM):** $7.75B
- **Diluted EPS (TTM):** $1.36
- **Forward Dividend & Yield:** $1.72 (6.22%)
- **Total Cash:** $14.99B

### Notable News & Analyst Commentary
- Pfizer announced **Phase 3 trial progress for PADCEV** and received **full FDA approval for BRAFTOVI** in colorectal cancer, representing oncology portfolio advancements.
- Analysts note **concerns about revenue forecasts and pipeline visibility**.
- One analyst report flags an **EPS decline expected in 2026**.
- A Seagen impairment charge and Metsera tolerability data were characterized as **"incrementally negative"** for Pfizer.
- **Earnings Date** is scheduled for **April 28, 2026**.
- Broader market context noted: major indices were down sharply on the referenced day, with the **VIX jumping ~15% to above 20**, driven by AI disruption fears affecting big tech.
</QuestionSource>


=== STOCK RETURN DISTRIBUTION (Programmatic Analysis) ===
Ticker: PFE | Window: 2026-03-02 to 2026-03-13 (9 trading days)
Latest close price: $27.65
Reference close price (2026-03-02): $27.65
Return so far: +0.00% (down from reference)

HISTORICAL BASE RATE (9-trading-day returns, N=2506 overlapping windows):
  P(positive 9-day return): 52.4%
  Mean return: +0.24%
  Median return: +0.25%
  Std dev: 4.41%
  Percentiles: 5th=-6.89%, 25th=-2.34%, 75th=+2.74%, 95th=+7.34%

RECENT CONTEXT:
  5-day trailing return: +3.75% (89th percentile historically)
  1-month trailing return: +6.92% (85th percentile historically)
  3-month trailing return: +9.30% (80th percentile historically)
  30-day realized volatility: 24.3% (annualized)

CONDITIONAL BASE RATES (same historical data, overlapping windows, filtered by current conditions):
  Unconditional:                           P(up) = 52.4% (N=2506)
  3-month return > 20%:                    P(up) = 17.1% (N=82, Δ=-35.4pp)
  Price in top decile of 52wk range:       P(up) = 58.3% (N=254, Δ=+5.8pp) <- CURRENTLY APPLICABLE
  Price in bottom decile of 52wk range:    P(up) = 48.1% (N=266, Δ=-4.3pp)
  Prior 5-day return > 0:                  P(up) = 53.8% (N=1296, Δ=+1.3pp) <- CURRENTLY APPLICABLE
  Prior 5-day return < 0:                  P(up) = 50.9% (N=1195, Δ=-1.6pp)
  30-day vol above median:                 P(up) = 47.9% (N=1238, Δ=-4.5pp) <- CURRENTLY APPLICABLE
  30-day vol below median:                 P(up) = 56.4% (N=1238, Δ=+3.9pp)

This is a PROGRAMMATIC computation from actual historical price data. Use the historical base rate as an anchor and adjust for current conditions.
=== END STOCK RETURN DISTRIBUTION ===

YOUR TASK:
1. Analyze the question and the pre-research context
2. Identify what information a skilled forecaster would need beyond what's already available
3. Generate 8 search queries to fill the remaining gaps

COVERAGE DIMENSIONS (ensure your queries collectively address these):
- Base rate: Historical frequency, distribution, or precedent for the outcome being forecast. How often has something like this happened before?
- Resolution mechanism: How exactly does this question resolve? What specific data source, metric, threshold, or event determines the outcome? What is the current state of that mechanism?
- Key drivers: The 1-3 most important causal factors that will determine the outcome. What moves this metric or makes this event more/less likely?
- Current state: Latest news, data points, or developments relevant to the question
- Contrarian check: Information that could support the less obvious outcome. What would make the unlikely scenario happen?

TYPE-SPECIFIC GUIDANCE:
- For binary "will X reach Y by Z" questions: Include a query for the historical base rate of X reaching Y in comparable timeframes. Also query the current trajectory/trend.
- For numeric questions: Query for recent values of the metric AND its primary upstream drivers. For financial metrics, query for upcoming scheduled events (data releases, FOMC meetings, earnings) before the resolution date.
- For multiple choice questions: Ensure at least one query is relevant to each substantive option. For catch-all/"other" options, query for the base rate of non-favored outcomes.

AVAILABLE TOOLS (only use tools listed here):
- Google: Keyword search. Write short queries (max 6 words) using terms likely to appear on relevant web pages. Best for reference pages, datasets, official reports.
- Google News: Keyword search over recent news articles. Max 6 words. Best for breaking news, recent events, and current developments.
- Agent: Your query will be processed by a reasoning model with web search capability. Write a detailed, multi-part query of up to 3 sentences. Best for complex questions needing synthesis across sources, base rate computation, or multi-factor analysis. IMPORTANT: Use exactly one Agent query, tagged [HISTORICAL], for base rate or reference class research. Do not use Agent for current events.
- AskNews: Semantic (meaning-based) news search. Write a descriptive 1-2 sentence natural language query focusing on the underlying topic, key actors, and context. Include relevant scope: geography, industry, time period. Avoid ambiguous acronyms. Best for finding conceptually related coverage even without exact keyword matches.
- FRED: Federal Reserve Economic Data. Use a FRED series ID (e.g., "UNRATE", "CPIAUCSL") or a plain-language description (e.g., "US unemployment rate"). Returns historical data with computed statistics. Only use for economic/financial data.
- yFinance: Yahoo Finance ticker symbol (e.g., "AAPL", "^GSPC"). Returns price history, fundamentals, analyst targets, and options data. Only use for stocks, indices, or ETFs.
- Google Trends: A search term (e.g., "hospital"). Returns 90-day search interest data with base rate analysis. Only use when the question specifically involves Google Trends data.

TAG each query as [HISTORICAL] (for base rates, reference classes, past data, background context) or [CURRENT] (for recent news, latest values, current developments, upcoming events). Aim for roughly 60% historical and 40% current. Include at least 2 of each.

Format your answer exactly as below. Each query on its own line. The source in parentheses, temporal tag in brackets. Do not wrap queries in quotes.

Analysis:
{Your analysis of the question, what the pre-research context already provides, what key information gaps remain, and your search strategy.}

Search queries:
1. [HISTORICAL] your query here (Google) -- Intent: what this query aims to find
2. [CURRENT] your query here (Google News) -- Intent: what this query aims to find
3. [HISTORICAL] your detailed multi-part query here (Agent) -- Intent: what this query aims to find
...
